[EN] PREPARATION OF MAYTANSINOID ESTERS<br/>[FR] PRÉPARATION D'ESTERS DE MAYTANSINOÏDE
申请人:BIO THERA SOLUTIONS LTD
公开号:WO2014094354A1
公开(公告)日:2014-06-26
Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
[EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT LE TRAITEMENT DE PATHOLOGIES ERB B2/NEU POSITIVES
申请人:BIO THERA SOLUTIONS LTD
公开号:WO2014094527A1
公开(公告)日:2014-06-26
Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
[EN] MAYTANSINOID DERIVATIVES<br/>[FR] DÉRIVÉS DE MAYTANSINOÏDE
申请人:BIO THERA SOLUTIONS LTD
公开号:WO2014094353A1
公开(公告)日:2014-06-26
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug- Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L- Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.